Surgical aortic valve replacement should remain the standard treatment for aortic stenosis

Oct 20, 2010

Despite the promising results of the "Placement of Aortic Transcatheter Valves (PARTNER) trial," featured in the Oct. 21 issue of the New England Journal of Medicine, a cardiothoracic surgeon from Boston Medical Center (BMC) believes that surgical aortic-valve replacement should remain the standard treatment of aortic stenosis. In the accompanying editorial, the author argues that Transcatheter aortic-valve implantation (TAVI) should be reserved for patients at inordinately high risk who are not suitable candidates for surgery and who have decreased life expectancy.

Aortic-valve replacement is the most effective treatment to alleviate symptoms and improve survival in patients with critical . However, a substantial number of these patients have coexisting conditions that preclude surgery. Since outcomes with medical management are poor, a less invasive and safer alternative to surgical is needed for this expanding group of patients.

TAVI has emerged as an alternative treatment for aortic stenosis in patients who are considered to have a high or prohibitive surgical risk. In this week's Journal, Martin B. Leon and his coauthors report the results of the PARTNER trial, a prospective, randomized, multicenter trial to determine the optimal method of treating patients with critical aortic stenosis who are considered not to be suitable candidates for surgery. Patients who underwent TAVI as compared with patients receiving medical management, had a significantly lower rate of death at one year, fewer hospital readmissions, and a reduction in cardiac symptoms. These improved outcomes were achieved, however, at the cost of a significant increase in the rate of major strokes and vascular events.

"Now that there is evidence-based clinical data to substantiate the benefits of TAVI in patients who are not suitable candidates for surgery, there will be a temptation to expand this technology to all patients with aortic stenosis," said editorial author Harold Lazar, MD, a professor of cardiothoracic surgery and Director of the Cardiothoracic Surgical Laboratories at the Boston University School of Medicine (BUSM).

According to Lazar a number of issues must be resolved prior to deciding what role TAVI may play in the treatment of aortic stenosis including criteria to determine who is not a candidate for surgical aortic-valve replacement, who should perform TAVI and where should it be performed. "Only when these issues are addressed can we determine where we go from here," he stressed.

"Given what we know, TAVI should not be performed in patients with long life expectancies. Prospective, adequately powered, randomized trials comparing TAVI with surgical aortic-valve replacement in both high-risk and low-risk patients will be necessary to further define the role of TAVI in the treatment of aortic stenosis," he added.

Explore further: Overwhelmed west Africa ramps up Ebola response

Provided by Boston University Medical Center

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Heart valves implanted without open-heart surgery

Jan 07, 2009

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center. Known as the PARTNER (Placement of ...

Major discovery in the treatment of aortic valve stenosis

Apr 18, 2008

A team of scientists from the Université de Montréal and the Montreal Heart Institute Research Centre, led by Dr. Jean-Claude Tardif, has completed an important study that show how a new type of medication can lead to an ...

Few complications one year after aortic valve implantation

Sep 21, 2009

Research presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), demonstrated an "exceptionally low" rate of complications ...

Recommended for you

Spain: Ebola test drug out of supply worldwide

52 minutes ago

Doctors treating a Spanish priest who was repatriated from West Africa on Monday after being diagnosed with the Ebola virus said there were no samples of experimental drug ZMapp available in the world right ...

A multiscale approach to Ebola response

2 hours ago

The Ebola outbreak in western Africa continues to spread uncontrolled, affecting thus far five countries. On September 16th, President Obama spoke at the Centers for Disease Control and Prevention headquarters ...

Overwhelmed west Africa ramps up Ebola response

17 hours ago

West Africa intensified its response to the deadly Ebola epidemic on Sunday, with Sierra Leone uncovering scores of dead bodies during a 72-hour shutdown and Liberia announcing hundreds of new hospital beds.

Sierra Leone reaches final day of Ebola lockdown

20 hours ago

Frustrated residents complained of food shortages in some neighborhoods of Sierra Leone's capital on Sunday as the country reached the third and final day of a sweeping, unprecedented lockdown designed to ...

User comments : 0